On August 1, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, reported that Company’s Management will participate in upcoming investor conferences in August (Press release, Selecta Biosciences, AUG 1, 2022, View Source [SID1234617205]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the conferences can be found below.

BTIG Biotechnology Conference 2022
Format: One-on-one investor meetings, attending virtually
Date: Monday, August 8 to Tuesday, August 9, 2022
Location: New York, NY

BTIG hosted events are intended for prospective and existing BTIG clients only. To schedule a meeting with the Company, please contact your BTIG representative.

Canaccord Genuity 42nd Annual Growth Conference
Format: Fireside chat and one-on-one investor meetings, attending in-person
Date: Wednesday, August 10, 2022
Time: 2:30 p.m. ET
Location: Boston, MA
Webcast: Click Here

An archived webcast of the Canaccord presentation will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

On August 1, 2022 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, reported that company management will participate in three upcoming investor conferences in August (Press release, Adicet Bio, AUG 1, 2022, View Source [SID1234617221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

BTIG Biotech Conference, August 8-9, 2022

Chen Schor, President & CEO, will participate in a fireside chat at the conference on Monday, August 8, 2022.
Wedbush Pacgrow Healthcare Conference, August 9-10, 2022

Chen Schor, President & CEO, will participate in a virtual panel discussion titled, "A View to a Kill(er) Cell – Part 1" on Wednesday, August 10, 2022, at 1:10 P.M. ET.
Canaccord Genuity Annual Growth Conference, August 8-11, 2022, Boston, Massachusetts

Chen Schor, President & CEO, will present a corporate overview on Thursday, August 11, 2022, at 11:00 A.M. ET.
The live audio webcast of the Canaccord Genuity presentation and Wedbush panel can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.

On August 1, 2022 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that it will host its second quarter 2022 financial results webcast on Monday, August 8th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time (Press release, Lantern Pharma, AUG 1, 2022, View Source [SID1234617173]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management intends to discuss the operating and financial results for the second quarter ended June 30, 2022 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.

A replay of the webinar will be available after the call on the investor relations section of the Company’s website: ir.lanternpharma.com.

On August 1, 2022 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL) (Press release, Cellectis, AUG 1, 2022, View Source [SID1234617190]). The Company plans to begin enrolling patients in the NatHaLi-01 study in the second half of the year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted that the FDA has cleared our IND application for UCART20x22", said André Choulika, PhD, Chief Executive Officer of Cellectis. "This is a very exciting product candidate, for two reasons: UCART20x22 will be our first dual allogeneic CAR T product candidate to enter clinical development, and dual targeting of CD20 and CD22, both validated targets in B-cell malignancies, has the potential to enhance tumor cell killing and increases the breadth of antigen targeting. These advantages may increase the addressable patient population and represent a potential therapeutic alternative to CD19-directed therapies.

UCART20x22 is also our first product candidate with fully integrated in-house development, showcasing our transformation into an end-to-end cell and gene therapy company, from discovery, process development, and GMP manufacturing to clinical development. We are very excited to start the clinical trial for patients with relapsed or refractory Non-Hodgkin Lymphoma."

UCART20x22 features TALEN-mediated disruptions of the TRAC gene (that has been shown to reduce the risk of graft-versus-host disease) and of the CD52 gene (to allow using a CD52-directed monoclonal antibody in patients’ preconditioning regimen and enhancing CAR T engraftment, expansion and persistence).

The Dose Finding portion of the study will evaluate UCART20x22 in a broad range of mature B-cell Non-Hodgkin lymphomas (NHL) which accounts for approximately 4% of all cancers[1]. It is estimated that 81,560 new cases of NHL and 20,720 deaths related to the disease occurred in the US in 2021[2], and 122,979 new cases of NHL and 49,684 deaths related to NHL occurred in Europe in 2020[3].

On August 1, 2022 Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Apollo Therapeutics Group Limited reported that they have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007 (camoteskimab), Avalo’s anti-IL-18 monoclonal antibody product (Press release, Avalo Therapeutics, AUG 1, 2022, View Source [SID1234617206]). Under the terms of the agreement, Apollo will assume responsibility for the future development of AVTX-007, including the ongoing clinical trial. Apollo will lead future clinical development in its selected therapeutic indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This transaction is critically important to Avalo. It extends our cash runway and allows us to increase our focus on our lead molecule, AVTX-002, and our ongoing phase 2 PEAK trial evaluating AVTX-002 for the treatment of non-eosinophilic asthma," said Garry A. Neil, MD, President and Chief Executive Officer of Avalo Therapeutics. "Furthermore, we are excited to transition camoteskimab to a capable and well-funded partner in Apollo Therapeutics whom we expect will progress the development of this promising asset to the potential benefit of patients and our collective financial interests."

"We are pleased to have entered into this agreement with Avalo and look forward to building upon the work done to date with camoteskimab," said Richard Mason, MD, chief executive of Apollo. "With our university partners we have built translational leadership in three core areas of biological focus – immunology, cell signaling, and cell stress responses and metabolism – and the addition of this Phase 2 ready antibody for an important inflammasome target substantially accelerates the growth of our pipeline in this area of immunology, where we are advancing additional preclinical programs. We seek further opportunities to acquire clinical assets in our areas of biological and therapeutic focus."

Pursuant to the license agreement, Avalo will receive within 5 days of execution of the agreement $5 million of upfront fee and an additional approximately $10 million as consideration for transfer activities. Apollo will also pay Avalo up to $74 million of milestones, as well as a royalty payment of a low single digit percentage of annual net sales.

The AVTX-007 program was originally licensed to Avalo by MedImmune Limited, a subsidiary of AstraZeneca plc, and such license was transferred to Apollo as part of the transaction.

About AVTX-007 (camoteskimab)
Camoteskimab is a high affinity, fully human monoclonal antibody targeting the proinflammatory cytokine IL-18.